Financial Ratios

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC
BSE5271.00-48.75 (-0.92 %)
PREV CLOSE ( ) 5319.75
OPEN PRICE ( ) 5329.95
BID PRICE (QTY) 5237.00 (1)
OFFER PRICE (QTY) 5360.00 (1)
VOLUME 1009
TODAY'S LOW / HIGH ( )5261.00 5377.10
52 WK LOW / HIGH ( )3102 7208
NSE5328.4513.7 (+0.26 %)
PREV CLOSE( ) 5314.75
OPEN PRICE ( ) 5329.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 7994
TODAY'S LOW / HIGH( ) 5255.00 5380.00
52 WK LOW / HIGH ( )3098 7220.95
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)39.7224.6437.3228.8821.78
   CEPS(Rs)46.2231.4245.3736.3227.75
   DPS(Rs)16.0010.002.001.000.00
   Book NAV/Share(Rs)234.45203.78181.83145.14119.48
   Tax Rate(%)25.9625.8226.5936.6425.07
Margin Ratios
   Core EBITDA Margin(%)16.3910.6516.5814.459.74
   EBIT Margin(%)13.3710.3815.6913.789.93
   Pre Tax Margin(%)13.3110.2615.5613.649.93
   PAT Margin (%)9.857.6111.428.657.44
   Cash Profit Margin (%)11.479.7013.8810.879.48
Performance Ratios
   ROA(%)9.376.6511.3110.579.34
   ROE(%)18.1312.7822.8321.8320.03
   ROCE(%)24.4917.3631.2434.6126.53
   Asset Turnover(x)0.950.870.991.221.25
   Sales/Fixed Asset(x)5.794.935.586.616.48
   Working Capital/Sales(x)2.232.172.593.885.02
Efficiency Ratios
   Fixed Capital/Sales(x)0.170.200.180.150.15
   Receivable days35.0338.5737.6235.6133.52
   Inventory Days59.8567.6472.5961.8957.68
   Payable days214.92220.48246.52229.92237.77
Valuation Parameters
   PER(x)81.76103.7180.6682.8091.75
   PCE(x)70.2681.3366.3465.8572.02
   Price/Book(x)13.8512.5416.5516.4816.72
   Yield(%)0.490.390.070.040.00
   EV/Net Sales(x)7.607.378.826.886.62
   EV/Core EBITDA(x)39.8458.8548.3742.8355.06
   EV/EBIT(x)56.5470.7255.9649.7566.36
   EV/CE(x)6.676.088.217.388.16
   M Cap / Sales8.097.939.257.196.86
Growth Ratio
   Net Sales Growth(%)24.50-0.98-2.1914.2127.55
   Core EBITDA Growth(%)89.44-31.9410.9452.6349.62
   EBIT Growth(%)60.41-34.4711.3558.4065.91
   PAT Growth(%)61.19-33.9829.2132.62110.15
   EPS Growth(%)61.19-33.9829.2132.62110.15
Financial Stability Ratios
   Total Debt/Equity(x)0.000.000.000.000.00
   Current Ratio(x)1.931.951.841.591.54
   Quick Ratio(x)1.541.591.421.141.10
   Interest Cover(x)213.8688.41117.60100.97
   Total Debt/Mcap(x)0.000.000.000.000.00

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.